on SENSORION (EPA:ALSEN)
Sensorion Participates in ASGCT Annual Meeting
Sensorion, a clinical-stage biotechnology firm specializing in novel therapies for hearing loss, has announced its participation in the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting from May 11-15, 2026, in Boston. The company will present two poster presentations during the event.
Laurent Desire, head of preclinical development at Sensorion, will present on SENS-601, an AAV-based gene therapy for a specific type of genetic deafness, on May 12. Concurrently, Marina Dos Santos will discuss the development and scale-up of a challenging AAV serotype enrichment process.
The presentations will be held from 5pm to 6:30pm ET at the Thomas M. Menino Convention & Exhibition Center. Sensorion aims to advance research and development in hearing loss treatments.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SENSORION news